Clinical Trials

Clinical Trials
molecule

OT-58 Phase 1/2  Enzyme  Therapy Clinical Trial — NOW ENROLLING

Orphan Technologies has initiated a first in human study of OT-58, an enzyme therapy that addresses the underlying enzyme deficit for patients living with classical homocystinuria. The goal of this trial is to evaluate the safety and efficacy of OT-58 in patients with classical homocystinuria and identify the appropriate dose. Patients between the ages of 12 and 65 years of age with classical homocystinuria may be eligible to join.

Link to ClinicalTrials.gov